| Ytd | 210.02% | |
| 1y | 285.07% |
| Open | 17.05 | Prev Close | 16.99 | Low | 16.95 | High | 17.22 | Mkt Cap | 90.42M |
| Vol | 6.94K | Avg Vol | 21.33K | EPS | 8.01 | P/E | 2.12 | Forward P/E | -0.72 |
| Beta | -1.67 | Short Ratio | 5.26 | Inst. Own | 76.27% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 16.76 | 200-d Avg | 12.07 | 1yr Est | 8.25 |
Shares of Rallybio Corporation (NASDAQ: RLYB - Get Free Report) traded up 1.9% during trading on Fri
About the Proposed Transaction Under the terms of the merger agreement, Rallybio will acquire Avenzo
eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, v
Rallybio stock jumps after announcing a $505 million merger with Candid Therapeutics, boosting cash
Following closing, pre-Transaction Rallybio equityholders are expected to own approximately 3.65% of
Rallybio reports strong Phase 1 results for RLYB116, showing full immune pathway control with good s
– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement
Rallybio Corporation (NASDAQ:RLYB) will effect a one-for-eight reverse stock split of its issued and
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.14) per share which beat the analyst consens
Rallybio (NASDAQ:RLYB) reported quarterly earnings of $0.36 per share which beat the analyst consens
Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific a
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consens
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 milli
Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically impro
– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Pl
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.21) per share which beat the analyst consens
Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 tria
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:RLYB) with a Buy and
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.25) per share which beat the analyst consens
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:RLYB) with a Buy and
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-th
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enl
On Monday, 369 companies set new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
Monday saw 196 companies set new 52-week lows.
Wednesday saw 219 companies set new 52-week lows.
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
Gainers Snail, Inc. (NASDAQ: SNAL) shares jumped 74.9% to $3.9350 after the company announced a $
On Tuesday, 951 companies hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 422 stocks made new 52-week lows.